← Back to Search

Other

NBI-1070770 for Depression

Phase 2
Recruiting
Research Sponsored by Neurocrine Biosciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

"This trial will test whether a new medication, NBI-1070770, is better than a placebo at reducing symptoms of depression in people with major depressive disorder."

Who is the study for?
This trial is for adults with recurrent or persistent Major Depressive Disorder (MDD) who've been on their current antidepressants for at least 8 weeks. They must be willing to continue these meds and follow all study rules.
What is being tested?
The trial tests NBI-1070770 against a placebo to see if it's better at improving depression symptoms in MDD patients. It measures how safe and tolerable the drug is compared to not receiving the active medication.
What are the potential side effects?
While specific side effects are not listed, common ones may include nausea, headache, dizziness, insomnia or sleepiness, changes in appetite, and potential mood swings.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: NBI-1070770: Medium DoseExperimental Treatment1 Intervention
Participants will receive medium-dose NBI-1070770.
Group II: NBI-1070770: Low DoseExperimental Treatment1 Intervention
Participants will receive low-dose NBI-1070770.
Group III: NBI-1070770: High DoseExperimental Treatment1 Intervention
Participants will receive high-dose NBI-1070770.
Group IV: PlaceboPlacebo Group1 Intervention
Participants will receive matching placebo.

Find a Location

Who is running the clinical trial?

Neurocrine BiosciencesLead Sponsor
75 Previous Clinical Trials
6,649 Total Patients Enrolled
3 Trials studying Depression
656 Patients Enrolled for Depression
Clinical Development LeadStudy DirectorNeurocrine Biosciences
24 Previous Clinical Trials
2,502 Total Patients Enrolled
2 Trials studying Depression
276 Patients Enrolled for Depression
~38 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top